Blog

On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA).  HG381 for injection is a new Category I Chemical Drug and is clinically intended to be used for the treatment of advanced tumors. HG381 is new molecular entity developed by HitGen basedRead more

#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15.  Please visit our virtual booth for more information on our oncology and preclinical services.  We look forward to see you. #Medicilon #Oncology #DrugDiscovery #AACR21Read more

Livzon Pharmaceutical Group Inc. (Livzon) obtained a “novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No. 2021L90001, 2021L90002, 2021L90003).  V-01 is to prevent diseases caused by novel coronavirus infection. V-01 is an innovative novel coronavirus recombinant protein vaccine developed by Livzon and the Institute of Biophysics,Read more

Medicilon will exhibit the 2021 SOT Virtual Annual Meeting from March 12-26.  Please visit our virtual booth to meet our VPs, Dr. Frank Wang, Dr. Mingzhu Zhang, Dr. Tao Ye and Sally Tang, for more information on our toxicology services.  We look forward to see you. #Medicilon #Toxicology #DrugDiscovery #SOT2021Read more

Thank you for your business, support and partnership in 2020!  Medicilon appreciates working with you and hope that the coming year will bring you happiness and success.Read more

Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines has the capacity to develop innovative drugs with global intellectual property rights, which has laid a solid foundation for the achievement of the company’s long-term sustainable development strategic goals. 3D011Read more

Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610 was the 14th innovative medicine that was approved of clinical trials. XZP is one small molecule agonist with high efficiency, high selectivity and novel structure that can significantly improve theRead more

Recently, Shanghai Medicilon was awarded the title of “Excellent Expert Workstation” by the Shanghai Academician and Expert Workstation Guidance Office and the title of “2020 Pudong New Area Excellent Academician and Expert Workstation” by the Pudong Science and Technology Association. Medicilon was awarded the title of “Excellent Expert Workstation” by the Shanghai Academician Expert WorkstationRead more

You may say that the Coronavirus Pandemic will define 2020. You may say that 2020 has given us more than our fair share of challenges and obstacles. But that doesn’t mean great achievements in 2020 didn’t occur! Medicilon embodies its motto of being “Innovation-driven, quality-focused” and keeps on maintaining and improving its technology and qualityRead more

Inflammatory immune diseases have gained much attention as the incidence has grown bigger each year. The diseases can affect many parts of human bodies and reduce the quality of life drastically. Yet the diagnoses can be frustrating and stressful because no one is sure what causes such diseases. The preclinical pharmacology department of Medicilon hasRead more